ACTU
ACTUATE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.58
−3.45%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +16.6%
- EBIT
- +14.5%
- EPS
- +49.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +24.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +10.6%
- Net income
- +18.5%
- EPS
- +67.5%
- Free cash flow
- +12.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026